Trial intelligence / Profile preview

Long-term safety of aliskiren + valsartan in essential hypertension

2006-002621-23Phase 3Completed

Sponsor
Novartis
Start
Aug 2006
Modality
Small Molecules
Countries
1
01

Overview

Phase 3, open-label, single-arm trial of aliskiren and valsartan in essential hypertension, sponsored by Novartis. Primary endpoint: Long-term safety. Started Aug 2006; status: completed.

02

Drugs

aliskirenvalsartan
03

Conditions

essential hypertension

Beyond the preview

Go deeper on 2006-002621-23.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2006-002621-23.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call